FHT 2344

Key Product Details

Product Description

FHT 2344 is a potent allosteric and ATP-competitive inhibitor of SMARCA2/SMARCA4 ATPases (also known as BRM/BRG1) of the BAF complex (IC₅₀ values are 13.8 and 26.1 nM at SMARCA2 and SMARCA4, respectively). FHT 2344 inhibits SMARCA2 transcriptional activity in a BRG1-mutant cell line and SMARCA4 transcription in a BRM-mutant cell line (IC₅₀ values are 29.8 and 30.2 nM, respectively). Dose-dependently reduces tumor growth in a uveal melanoma xenograft model and suppresses SOX10 transcription.

Licensing Information

Sold under license from Foghorn Therapeutics

Product Specifications for FHT 2344

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for FHT 2344

The following data is based on the product molecular weight 528.60.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	3.78 mL	18.92 mL	37.84 mL
2.5 mM	0.76 mL	3.78 mL	7.57 mL
5 mM	0.38 mL	1.89 mL	3.78 mL
25 mM	0.08 mL	0.38 mL	0.76 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Centore Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers. Cancer Res.

Product Documents for FHT 2344